Cosmos Holdings (V67A) AI Stock Analysis

1 Followers

Cosmos Holdings

(Frankfurt:V67A)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthRevenue growth demonstrates continued demand for the company’s pharmaceutical and nutraceutical offering. If sustained, a larger sales base can improve operating leverage, support broader market reach, and provide more room to absorb fixed costs over the next several quarters.

Negative Factors

Persistent UnprofitabilityVery low gross profitability and a large operating loss indicate that current sales do not cover the company’s cost structure. Persistent net losses weaken retained capital and make revenue growth less valuable until margins and operating efficiency improve materially.

Cosmos Holdings (V67A) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 16.30M
Dividend Yield: ―
Average Volume (3M): 415
Price to Earnings (P/E): -4.9
Beta (1Y): 1.18
Revenue Growth: 24.77%
EPS Growth: 38.49%
Country: Germany
Employees: 163
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Pharmaceuticals

Cosmos Holdings Business Overview & Revenue Model

Company Description

Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. Th...

Cosmos Holdings Risk Analysis

Cosmos Holdings disclosed 10 risk factors in its most recent earnings report. Cosmos Holdings reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Cosmos Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:V67A against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AYTU	61Neutral	$19.45M	-1.30	-52.89%	―	-13.27%	27.11%
SCYX	53Neutral	$33.14M	-2.74	-18.65%	―	543.96%	72.49%
RMTI	52Neutral	$29.74M	-4.75	-16.04%	―	-3.96%	7.97%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TXMD	50Neutral	$21.07M	230.86	-0.80%	―	27.78%	52.88%
PRPH	41Neutral	$83.35K	-0.00	-1358.66%	―	―	―

* Healthcare Sector Average

Performance Comparison

DE:V67A and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:V67A	Cosmos Holdings	4.13	-8.14	-66.36%
PRPH	Prophase Labs	0.01	-2.64	-99.62%
RMTI	Rockwell Medical	7.03	-1.63	-18.78%
TXMD	Therapeuticsmd Inc	1.87	0.35	23.03%
SCYX	SCYNEXIS Inc	3.21	-1.41	-30.49%
AYTU	Aytu BioScience	1.78	-0.20	-10.10%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Cosmos Holdings AI Stock Analysis